ArticleMedicine2025
Migraine and cochlear disease: A 2-sample bidirectional Mendelian randomized study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Migraine and auditory dysfunction: beyond comorbidity.Journal of neurology · 2026Review
- Migraine-induced cochlear injury triggers ZBP1-mediated PANoptosis via CGRP signaling.The journal of headache and pain · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to explore the potential causal relationship between migraine and cochlear disease by using a bidirectional Mendelian randomization (MR) approach. We searched datasets related to migraine in the FinnGen database and genome-wide association studies catalog. We conducted 2-sample MR analyses. Instrumental variables were selected based on stringent criteria, including genome-wide significance, clumping to ensure independence, and exclusion of palindromic single nucleotide polymorphisms and those associated with confounders. The primary MR analysis employed the inverse-variance weighted (IVW) method supplemented by sensitivity analyses using the Weighted Median and MR-Egger (MR-Egger) methods to address potential pleiotropy. MR analyses suggested a causal relationship between migraine and increased risk of cochlear disease. MR analyses suggested that migraine was associated with an increase in tinnitus (IVWMR odds ratio (OR) = 1.516, 95% confidence interval (CI): 1.064-2.159, P = .021). Migraine was also associated with an increase in vertigo (IVW MR OR = 1.631, 95% CI: 1.003-2.651, P = .049). Medication use (antimigraine preparations) was associated with an increase in sudden idiopathic hearing loss (IVW MR OR = 1.187, 95% CI: 1.023-1.378, P = .024). Medication use (antimigraine preparations) was also associated with an increase in other hearing loss (IVW MR OR = 1.085, 95% CI: 1.007-1.169, P = .032). Migraine with no aura triptan was associated with an increase in tinnitus (IVW MR OR = 1.226, 95% CI: 1.075-1.398, P = .002). These findings were robust across various sensitivity analyses, including MR-Egger and MR Pleiotropy RESidual Sum and Outlier, supporting the absence of pleiotropy and outliers. Our results establish a causal link between migraine and cochlear disease, indicating that migraine may exacerbate cochlear disease. Additionally, these findings strengthen the evidence-based medical foundation of the relationship between migraines and cochlear disease. They offer theoretical support for future migraine aimed at treating cochlear disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.